Immunocore says it is continuing to work closely with the European Medicines Agency on the marketing application for its novel T-cell receptor (TCR) therapy, tebentafusp, after the agency held fire on adopting an opinion on whether the drug should receive EU-wide approval.
Tebentafusp, intended for treating the rare and aggressive cancer of the eye, metastatic uveal melanoma, continues to be reviewed on...






